BPC-157: not FDA-approved
Individual results vary, and benefits are not guaranteed
The regulatory pathway for topical cosmetic ingredients is substantially different from injectable drug compounds
For example, when L-NAME, a compound that inhibits NOS and reduces NO production, was administered, BPC-157 seemed to mitigate some of the resulting pathology
Energy and metabolism peptides are frequently combined with NAD+ IV therapy, hormone optimization, and nutrition counseling for a comprehensive metabolic approach.
Additionally, BPC-157 appears to influence nitric oxide synthase activity, thereby affecting vascular tone and tissue perfusion, which are critical components of the healing response